News

FDA Efforts to Advance Development of Gene Therapies


 

The field of gene therapy has progressed rapidly since these guidances were first issued. Therefore, the FDA is updating these guidances to provide sponsors with the agency’s most up-to-date thinking.

Our goal is to help promote safe and effective product development in this field. We’ll continue to work with the product sponsors to help make the development and approval of these innovative gene therapies more efficient, while putting in place the regulatory controls needed to ensure that the resulting therapies are both safe and effective. We’ll also make full use of our expedited programs such as breakthrough therapy designation and regenerative medicine advanced therapy designation whenever possible.

Gene therapy represents one of the most promising opportunities for developing highly effective and even curative treatments for many vexing disorders. Some of these products are almost certainly going to change the contours of medical practice, and the destiny of patients with some debilitating diseases.

The FDA’s goal is to help these innovations advance in a framework that assures the safety and effectiveness of these resulting treatments, and continues to build peoples’ confidence in this novel area of medicine.

–Scott Gottlieb, MD

Pages

Recommended Reading

Morgan Leary Vaughan Foundation
MDedge Neurology
Osteogenesis Imperfecta Foundation (OIF)
MDedge Neurology
Mohammed Sanjak, PhD
MDedge Neurology
Guidance coming for mTOR inhibitors in infantile TSC
MDedge Neurology
Myelin antibody predicts ADEM relapse
MDedge Neurology
Experimental Therapy Shows Promise in Early-Stage Huntington’s Disease
MDedge Neurology
FDA Commissioner Comments on Signing of the Right to Try Act
MDedge Neurology
FDA approves Epidiolex for Lennox-Gastaut syndrome and Dravet syndrome
MDedge Neurology
FDA Approves a Cannabinoid Medicine for Two Forms of Epilepsy
MDedge Neurology
Patisiran May Reduce Neuropathy in Patients With hATTR Amyloidosis
MDedge Neurology